Abstract Number: 493 • 2013 ACR/ARHP Annual Meeting
A Real-World Risk Analysis Of Biological Treatment (Adalimumab and Etanercep) In Country With High Prevalence Of Tuberculosis and Hepatitis B/C
Background/Purpose: Biologics have been widely utilized in many rheumatic diseases. Risks associated with the use of biological treatments are revealed in many published studies. Nevertheless,…Abstract Number: 2318 • 2013 ACR/ARHP Annual Meeting
Disease Activity in Moderate and Severe Rheumatoid Arthritis At Discontinuation in 10-Year Open-Label Extension Studies With Etanercept
Background/Purpose: Retention rates may be used as a surrogate of long-term effectiveness of drug therapy in open-label studies. Studies have reported that patients (pts)…Abstract Number: 471 • 2013 ACR/ARHP Annual Meeting
Etanercept 25 Mg Once Weekly Program For Rheumatoid Arthritis, Psoriatic Arthropathy and Ankylosing Spondylitis Patients In Sustained Clinical and Radiological Remission
Etanercept 25 mg once weekly program for rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients in sustained clinical and radiological remissionBackground/Purpose: Etanercept 50mg/week (ETN50) has…Abstract Number: 2184 • 2013 ACR/ARHP Annual Meeting
Application Of The Bonexpert Method For Bone Age and Bone Health Assessment In Patients With Juvenile Idiopathic Arthritis
Background/Purpose: Both the maturation of bone and its mineral density are affected by chronic inflammation in juvenile idiopathic arthritis (JIA). Bone age is in most…Abstract Number: 427 • 2013 ACR/ARHP Annual Meeting
US Veterans With Rheumatoid Arthritis Who Switch Among Tumor Necrosis Factor Blocking Agents Have No Additional Clinical Benefit With The Change In Therapy and Incur Higher Costs
Background/Purpose: While tumor necrosis factor (TNF) blockers can be effective in treating rheumatoid arthritis (RA), the benefit of switching among TNF blockers is not clear.…Abstract Number: 2030 • 2013 ACR/ARHP Annual Meeting
Comparative Immunogenicity Of Tumor Necrosis Factor Inhibitors: Impact On Clinical Efficacy and Tolerability In The Management Of Autoimmune Diseases: A Systematic Review and Meta-Analysis
AbstractBackground/Purpose: Tumor necrosis factor inhibitors (TNFi) are a mainstay in the treatment of rheumatoid arthritis (RA), as well as the management of spondyloarthritis (SpA) and…Abstract Number: 355 • 2013 ACR/ARHP Annual Meeting
Response To Etanercept With Or Without Methotrexate Combination Therapy In Patients With Psoriatic Arthritis
Background/Purpose: Randomized controlled trials in psoriatic arthrtitis (PsA) have allowed treatment with TNF inhibitors (TNFi) as monotherapy as well as co-medication with methotrexate (MTX), but…Abstract Number: 1862 • 2013 ACR/ARHP Annual Meeting
Target-Directed Development Of a Proposed Biosimilar Etanercept, GP2015: Comparability Of In Vitro Target Binding and Pre-Clinical Efficacy and Pharmacokinetics
Background/Purpose: Biosimilars are copy versions of existing biologic medicines that have lost patent exclusivity and are approved via stringent regulatory pathways. Biosimilars are designed to…Abstract Number: 280 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy Of Etanercept In Paediatric Subjects With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Or Psoriatic Arthritis
Background/Purpose: Etanercept (ETN) is approved for the treatment of pediatric patients with the polyarticular subtype of juvenile idiopathic arthritis (JIA). In addition, based on the…Abstract Number: 1843 • 2013 ACR/ARHP Annual Meeting
Treatment With Staphyloccocal Protein A Which Is Immuno-Modulatory In The Murine Collagen Arthritis Model, Does Not Increase Infection Severity In Murine Listeria Or Candida Challenge Models, In Contrast To Anti-TNF Treatment
Background/Purpose: PRTX-100 is a highly-purified GMP staphylococcal protein A (SpA) that is currently in Phase I trials in patients with active rheumatoid arthritis (RA). SpA…Abstract Number: 268 • 2013 ACR/ARHP Annual Meeting
Inflammatory Bowel Disease In Juvenile Idiopathic Arthritis Patients Upon Biologics
Background/Purpose: Inflammatory bowel disease (IBD) is a matter of interest in patients with juvenile idiopathic arthritis (JIA) treated with biologics. Methods: Baseline demografics, clinical characteristics…Abstract Number: 1826 • 2013 ACR/ARHP Annual Meeting
Immune Complex Formation By Adalimumab Contributes Significantly To Its Inhibitory Effect On TNF-Enhanced Human Osteoclast Development Even In The Absence Of Fc Receptor Binding
Background/Purpose: TNF-alpha (TNFa) has been shown to contribute to osteoclastogenesis independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast development. …Abstract Number: 1546 • 2013 ACR/ARHP Annual Meeting
Patient-Reported Outcomes of Etanercept in Early Non-Radiographic Axial Spondyloarthritis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Background/Purpose: Limited data are available on the efficacy of anti-TNF agents in non-radiographic axial spondyloarthritis (nr-axSpA). This analysis compares the impact of etanercept (ETN) vs…Abstract Number: 1004 • 2012 ACR/ARHP Annual Meeting
A Unique Single Nucleotide Polymorphism in the 3’ UTR of the MED29 Gene On Chromosome 19 Is Associated with the Clinical Outcome of Different Biologic Response Modifiers
Background/Purpose: Due to the wide range of highly specific and effective biologic response modifiers that are available today for the treatment of RA it has…Abstract Number: 2465 • 2012 ACR/ARHP Annual Meeting
Seroresponse Rates After Influenza Vaccination in Rheumatoid Arthritis Patients Treated with Biological Agents During the 2011–2012 Flu Season
Background/Purpose: At present, annual vaccination against influenza is recommended for rheumatoid arthritis (RA) patients. However, whether humoral responses to influenza vaccine are impaired in RA…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- Next Page »